Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.

PURPOSE Up to 26% of patients with pathologically organ confined prostate cancer will experience clinical progression after radical prostatectomy. We attempted to identify patients at greatest risk for future clinical failure despite a favorable pathological outcome. MATERIALS AND METHODS The study group included 904 patients treated with bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for disease confined to the prostate gland. Preoperative serum prostate specific antigen (PSA), clinical stage, pathological grade and stage, and deoxyribonucleic acid (DNA) ploidy were evaluated by multivariate analysis to determine relative value in predicting treatment failure. A prognostic scoring system was created using the regression coefficients from the Cox multivariate model to classify patients further according to risk of progression. RESULTS Preoperative PSA concentration, clinical stage, grade and DNA ploidy were significant univariate predictors of progression (p < 0.0001), whereas pathological stage was not (p = 0.2). Multivariate analysis identified pathological grade (p < 0.0001), preoperative serum PSA concentration (p = 0.0006) and DNA ploidy (p = 0.0089) as independent predictors of progression. The prognostic scoring system separated the patients into 5 distinct groups. Patients with the lowest score had a 92% progression-free survival rate at 5 years, compared to only 39% of those with the highest scores. CONCLUSIONS Patients believed to be at higher risk for cancer progression despite having organ confined disease might be targeted for adjuvant therapy and closer surveillance, while those at low risk may be followed less often.

[1]  T. Therneau,et al.  Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. , 1989, Mayo Clinic proceedings.

[2]  O. Culp Radical Perineal Prostatectomy: Its Past, Present and Possible Future , 1967 .

[3]  M. Frydenberg,et al.  Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. , 1993, Urology.

[4]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. , 1988 .

[7]  J. McNeal Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. , 1992, Human pathology.

[8]  T. Stamey,et al.  Morphometric and clinical studies on 68 consecutive radical prostatectomies. , 1988, The Journal of urology.

[9]  T. Therneau,et al.  Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. , 1989, The Journal of urology.

[10]  P. Walsh,et al.  Cancer control following anatomical radical prostatectomy: an interim report. , 1991, The Journal of urology.

[11]  M. Blute,et al.  Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. , 1991, The Journal of urology.

[12]  D. Cox Regression Models and Life-Tables , 1972 .

[13]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[14]  Montie Je 1992 staging system for prostate cancer , 1993 .

[15]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[16]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[17]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[18]  H. Zincke,et al.  Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) , 1991, The Journal of urology.

[19]  J. Eggleston,et al.  Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. , 1972, The Journal of urology.

[20]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[21]  D. Bostwick,et al.  Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.

[22]  G. Gray,et al.  The palpable nodule of prostatic cancer. Results 15 years after radical excision. , 1968, JAMA.

[23]  T. Fleming,et al.  Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. , 1984, The Journal of urology.

[24]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[25]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[26]  D. Hoak,et al.  Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. , 1990, The Journal of urology.

[27]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .

[28]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[29]  A. Partin,et al.  Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. , 1995, The Journal of urology.

[30]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[31]  H. Zincke Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. , 1989, Urology.